Neoplasms, Plasma Cell: all 2,314 studies
Page 16 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDSCompletedNCT02215980Phase 3
- Role of Osteocytes in Myeloma Bone DiseaseCompletedNCT02212262
- Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)CompletedNCT02206503Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple MyelomaNo longer availableNCT02204553
- Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02204241Phase 1/2
- Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-LigandsCompletedNCT02203825Phase 1
- Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple MyelomaCompletedNCT02197221Phase 3
- Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple MyelomaCompletedNCT02189343Phase 1
- Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive MyelomaCompletedNCT02188537Phase 2
- Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma PatientsTerminatedNCT02188368Phase 2
- Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple MyelomaStatus unknownNCT02187731
- Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)CompletedNCT02185820Phase 1/2
- Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell MobilizationStatus unknownNCT02184897Not applicable
- An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02182141Phase 1
- Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma PatientsTerminatedNCT02177682Phase 1
- Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT02176213Phase 2
- A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.CompletedNCT02164955
- Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and BortezomibStatus unknownNCT02158702Phase 2
- A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple MyelomaCompletedNCT02157636Phase 1
- Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in MyelomaWithdrawnNCT02155634Phase 3
- Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple MyelomaStatus unknownNCT02145715Phase 1/2
- Treatment Optimization in Patients With Untreated Multiple MyelomaTerminatedNCT02145598Phase 2/3
- Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT02144038Phase 1
- UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered TrametinibWithdrawnNCT02140840Phase 2
- CART-19 for Multiple MyelomaCompletedNCT02135406Phase 1
- Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family CaregiversCompletedNCT02129569Not applicable
- A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02116569Phase 1
- A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered VemurafenibWithdrawnNCT02115035Phase 1/2
- Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnNCT02114502Phase 2
- Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMMCompletedNCT02112175Phase 3
- Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaTerminatedNCT02110563Phase 1
- Microdose Study of Melphalan, Bortezomib and DexamethasoneStatus unknownNCT02109861Early Phase 1
- Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple MyelomaCompletedNCT02103335Phase 1
- Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02101944Phase 1
- Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02095834Phase 1
- Oligosecretary Myeloma: Prevalence and Its Clinical SignificanceCompletedNCT02095379
- Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral NeuropathyStatus unknownNCT02093910Phase 2
- A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)CompletedNCT02092922Phase 2
- Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.Status unknownNCT02086942Phase 2
- Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple MyelomaWithdrawnNCT02082405Phase 2
- Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma SurvivorsStatus unknownNCT02078518
- Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT02077959Phase 1
- Non-interventional Study With Pomalidomide (Imnovid®)CompletedNCT02075996
- A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02072863Phase 1/2
- Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDsCompletedNCT02066454Phase 3
- Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.TerminatedNCT02063113Not applicable
- Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple MyelomaCompletedNCT02056756Phase 1/2
- Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal InsufficiencyCompletedNCT02045017Phase 2
- Comprehensive Frailty AssessmentCompletedNCT02033928
- Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple MyelomaTerminatedNCT02030483Phase 1
- Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple MyelomaStatus unknownNCT02027220Phase 2
- Evaluation of Cardiotoxic Effects of BortezomibCompletedNCT02026505
- Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma.Status unknownNCT02024815Phase 3
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaCompletedNCT01998971Phase 1
- A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple MyelomaCompletedNCT01989325Phase 2
- Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedNCT01985477Phase 1
- A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple MyelomaCompletedNCT01965353Phase 1
- Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple MyelomaCompletedNCT01955395Not applicable
- Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple MyelomaTerminatedNCT01954784Phase 1
- Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309
- Pharmacokinetic Study of Thalidomide in Subjects With Multiple MyelomaCompletedNCT01937442Phase 1
- Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01936090Phase 1
- Busulfan and Melphalan Conditioning in Multiple MyelomaStatus unknownNCT01923935Phase 2
- Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years OldCompletedNCT01916252Phase 3
- Maintenance Therapy With Subcutaneous BortezomibCompletedNCT01913730Phase 2
- Study to Evaluate Optimized Retreatment and Prolonged Therapy With BortezomibCompletedNCT01910987Phase 3
- Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.CompletedNCT01908621Phase 3
- Acupuncture for Chemotherapy-induced Peripheral NeuropathyStatus unknownNCT01892852Not applicable
- Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138Status unknownNCT01886976Phase 1/2
- A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple MyelomaStatus unknownNCT01868828Phase 4
- Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple MyelomaCompletedNCT01861340Early Phase 1
- 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple MyelomaStatus unknownNCT01859234Not applicable
- A Phase II Study of BI-505 in Smoldering Multiple MyelomaTerminatedNCT01838369Phase 2
- Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple MyelomaCompletedNCT01829412Not applicable
- Cancer Stem Cells in Multiple MyelomaCompletedNCT01820546
- Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell TransplantWithdrawnNCT01812720Phase 2
- Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in ChinaStatus unknownNCT01812096Phase 1/2
- Multiple Myeloma and ExerciseCompletedNCT01809717Not applicable
- A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyCompletedNCT01794507Phase 1
- Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple MyelomaStatus unknownNCT01792102Phase 1/2
- First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02CompletedNCT01790737Phase 2
- Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted ImagingStatus unknownNCT01780766
- SST0001 (Roneparstat) in Advanced Multiple MyelomaCompletedNCT01764880Phase 1
- Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01758328Phase 1
- An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem CellsCompletedNCT01753453Phase 2
- SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM PatientsCompletedNCT01749969Phase 1
- Geriatric Assessments in Senior Adults With Multiple MyelomaCompletedNCT01746030
- An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)TerminatedNCT01742793Phase 1
- A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple MyelomaCompletedNCT01723020Phase 1
- Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)CompletedNCT01720875Phase 2
- Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple MyelomaCompletedNCT01718899Phase 1
- Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus unknownNCT01716364Phase 1
- Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01711528Phase 1
- Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01701076Phase 2
- Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma PatientsCompletedNCT01697839
- Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple MyelomaStatus unknownNCT01695590Phase 1/2
- C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CTCompletedNCT01691300Not applicable
- Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01689987Phase 1
- Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed MyelomaStatus unknownNCT01686386Phase 1/2